Rhumbline Advisers Cytokinetics Inc Transaction History

Rhumbline Advisers

  • $109 Billion
  • Q3 2024

A detailed history of Rhumbline Advisers transactions in Cytokinetics Inc stock. As of the latest transaction made, Rhumbline Advisers holds 378,676 shares of CYTK stock, worth $18.6 Million. This represents 0.02% of its overall portfolio holdings.

Number of Shares
378,676
Previous 379,257 0.15%
Holding current value
$18.6 Million
Previous $20.5 Million 2.7%
% of portfolio
0.02%
Previous 0.02%

Shares

29 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 12, 2024
SELL
$51.22 - $60.16 $29,758 - $34,952
-581 Reduced 0.15%
378,676 $20 Million
Q2 2024

Aug 01, 2024
BUY
$47.86 - $75.05 $3.48 Million - $5.45 Million
72,618 Added 23.68%
379,257 $20.5 Million
Q1 2024

May 09, 2024
BUY
$63.75 - $108.06 $1.58 Million - $2.68 Million
24,797 Added 8.8%
306,639 $21.5 Million
Q4 2023

Feb 08, 2024
BUY
$26.88 - $83.49 $187,434 - $582,175
6,973 Added 2.54%
281,842 $23.5 Million
Q3 2023

Nov 09, 2023
BUY
$29.46 - $36.61 $88,527 - $110,013
3,005 Added 1.11%
274,869 $8.1 Million
Q2 2023

Aug 08, 2023
BUY
$32.62 - $40.75 $416,426 - $520,214
12,766 Added 4.93%
271,864 $8.87 Million
Q1 2023

May 11, 2023
BUY
$33.36 - $45.71 $388,310 - $532,064
11,640 Added 4.7%
259,098 $9.12 Million
Q4 2022

Feb 14, 2023
BUY
$35.77 - $51.11 $267,774 - $382,609
7,486 Added 3.12%
247,458 $11.3 Million
Q3 2022

Nov 10, 2022
BUY
$38.54 - $54.52 $852,658 - $1.21 Million
22,124 Added 10.16%
239,972 $11.6 Million
Q2 2022

Aug 11, 2022
BUY
$33.93 - $48.92 $535,245 - $771,713
15,775 Added 7.81%
217,848 $8.56 Million
Q1 2022

May 12, 2022
BUY
$29.74 - $46.0 $432,776 - $669,392
14,552 Added 7.76%
202,073 $7.44 Million
Q4 2021

Feb 10, 2022
BUY
$34.35 - $46.38 $18,033 - $24,349
525 Added 0.28%
187,521 $8.55 Million
Q3 2021

Nov 12, 2021
SELL
$18.54 - $35.74 $159,536 - $307,542
-8,605 Reduced 4.4%
186,996 $6.68 Million
Q2 2021

Aug 05, 2021
SELL
$19.79 - $26.99 $150,720 - $205,555
-7,616 Reduced 3.75%
195,601 $3.87 Million
Q1 2021

May 06, 2021
BUY
$18.57 - $25.68 $84,270 - $116,535
4,538 Added 2.28%
203,217 $4.73 Million
Q4 2020

Feb 10, 2021
BUY
$15.26 - $28.61 $185,790 - $348,326
12,175 Added 6.53%
198,679 $4.13 Million
Q3 2020

Nov 12, 2020
BUY
$20.58 - $28.96 $250,767 - $352,877
12,185 Added 6.99%
186,504 $4.04 Million
Q2 2020

Aug 13, 2020
SELL
$11.15 - $24.64 $70,401 - $155,576
-6,314 Reduced 3.5%
174,319 $4.11 Million
Q1 2020

May 06, 2020
BUY
$8.75 - $16.3 $29,802 - $55,517
3,406 Added 1.92%
180,633 $2.13 Million
Q4 2019

Feb 05, 2020
BUY
$7.95 - $11.84 $89,238 - $132,904
11,225 Added 6.76%
177,227 $1.88 Million
Q3 2019

Oct 23, 2019
BUY
$10.82 - $14.25 $57,281 - $75,439
5,294 Added 3.29%
166,002 $1.89 Million
Q2 2019

Aug 14, 2019
BUY
$7.95 - $11.25 $108,525 - $153,573
13,651 Added 9.28%
160,708 $1.81 Million
Q1 2019

May 01, 2019
SELL
$5.95 - $10.19 $5,813 - $9,955
-977 Reduced 0.66%
147,057 $1.19 Million
Q4 2018

Jan 31, 2019
BUY
$5.91 - $9.29 $142,838 - $224,530
24,169 Added 19.51%
148,034 $936,000
Q3 2018

Nov 07, 2018
BUY
$6.4 - $9.85 $25,824 - $39,744
4,035 Added 3.37%
123,865 $1.22 Million
Q2 2018

Aug 06, 2018
BUY
$6.9 - $9.9 $68,434 - $98,188
9,918 Added 9.02%
119,830 $995,000
Q1 2018

May 02, 2018
BUY
$7.2 - $10.05 $31,622 - $44,139
4,392 Added 4.16%
109,912 $791,000
Q4 2017

Feb 09, 2018
BUY
$7.25 - $15.65 $126,614 - $273,311
17,464 Added 19.83%
105,520 $860,000
Q3 2017

Nov 06, 2017
BUY
$12.0 - $15.0 $1.06 Million - $1.32 Million
88,056
88,056 $1.28 Million

Others Institutions Holding CYTK

# of Institutions
410
Shares Held
125M
Call Options Held
4.6M
Put Options Held
2.43M
View Full List

About CYTOKINETICS INC

CYTK Quotes by TradingView
  • Ticker CYTK
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 94,144,096
  • Market Cap $4.62B
  • Description
  • Cytokinetics, Incorporated, a late-stage biopharmaceutical company, focuses on discovering, developing, and commercializing muscle activators and inhibitors as potential treatments for debilitating diseases. The company develops small molecule drug candidates primarily engineered to impact muscle function and contractility. Its drug candidates i...
More about CYTK
Track This Portfolio

Track Rhumbline Advisers Portfolio

Follow Rhumbline Advisers and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Rhumbline Advisers, based on Form 13F filings with the SEC.

News

Stay updated on Rhumbline Advisers with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email